ACELYRIN Inc (SLRN) News

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 8-K/A - Current report: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its...

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical...

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Sur

Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept...

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to...